CASI Pharmaceuticals, Inc.

OTCPK:CASI.F Stock Report

Market Cap: US$2.2m

CASI Pharmaceuticals Management

Management criteria checks 2/4

CASI Pharmaceuticals' CEO is Wei-Wu He, appointed in Feb 2026, has a tenure of less than a year. directly owns 9.78% of the company’s shares, worth $211.11K. The average tenure of the management team and the board of directors is 2.9 years and 10.9 years respectively.

Key information

Wei-Wu He

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership9.8%
Management average tenure2.9yrs
Board average tenure10.9yrs

Recent management updates

Recent updates

Analysis Article • Nov 25

Lacklustre Performance Is Driving CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) 27% Price Drop

Unfortunately for some shareholders, the CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) share price has dived 27% in the...
Analysis Article • Sep 30

Little Excitement Around CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues As Shares Take 43% Pounding

CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) shareholders won't be pleased to see that the share price has had a very...
Analysis Article • Sep 09

One CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Analyst Just Made A Major Cut To Next Year's Estimates

Market forces rained on the parade of CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) shareholders today, when the covering...
Analysis Article • Aug 16

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shares Bounce 80% But Its Business Still Trails The Industry

CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) shareholders would be excited to see that the share price has had a great...
Analysis Article • Jul 02

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Not Doing Enough For Some Investors As Its Shares Slump 30%

To the annoyance of some shareholders, CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) shares are down a considerable 30% in...
Analysis Article • Mar 21

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shares Lagging The Industry But So Is The Business

You may think that with a price-to-sales (or "P/S") ratio of 1.6x CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) is...
Analysis Article • Nov 26

The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34%

The CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) share price has fared very poorly over the last month, falling by a...
Analysis Article • May 21

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) shareholders are no doubt pleased to see that the share price has bounced...
Analysis Article • Mar 12

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

To the annoyance of some shareholders, CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) shares are down a considerable 26% in...
Analysis Article • Dec 18

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Despite an already strong run, CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) shares have been powering on, with a gain of...
Analysis Article • Sep 02

We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • May 20

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 23

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

Casi Pharmaceuticals (NASDAQ:CASI) is selling its equity interest of 12.0098% in Juventas Biotechnology (Tianjin) to Shenzhen Jiadao Gongcheng Equity Investment Fund for RMB240.87M (~$34.03M). Casi's unit Casi Biopharmaceuticals (Wuxi) signed the equity transfer agreement with Jiadao under which one payment will be made after signing and the second after the equity transaction is completed, the Rockville, Md.-based company said in a Sept. 23 press release. "The completion of the equity transfer transaction will strengthen CASI's balance sheet by providing CASI with sufficient cash to operate until, at least, the end of 2023," said Casi's Chairman and CEO Wei-Wu He. The CEO added that Casi expects Juventas to file an application an application to the Chinese drug regulator seeking approval of CNCT-19 for  B-cell acute lymphoblastic leukemia. "CASI and Juventas will continue to maintain a working partnership, focusing on product launch and co-marketing for CNCT-19," the CEO commented.
Seeking Alpha • Aug 11

CASI Pharmaceuticals Q2 2022 Earnings Preview

CASI Pharmaceuticals (NASDAQ:CASI) is scheduled to announce Q2 earnings results on Friday, August 12th, before market open. The consensus EPS Estimate is -$0.61 (-1120.0% Y/Y) and the consensus Revenue Estimate is $7.87M (+9.9% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Analysis Article • May 26

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 14

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Shareholders in CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) may be thrilled to learn that the analysts have just...

CEO Compensation Analysis

How has Wei-Wu He's remuneration changed compared to CASI Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$48m

Sep 30 2025n/an/a

-US$49m

Jun 30 2025n/an/a

-US$47m

Mar 31 2025n/an/a

-US$40m

Dec 31 2024n/an/a

-US$39m

Sep 30 2024n/an/a

-US$31m

Jun 30 2024n/an/a

-US$27m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023n/an/a

-US$27m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$38m

Dec 31 2022n/an/a

-US$41m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$10mUS$322k

-US$37m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$819kUS$578k

-US$48m

Sep 30 2020n/an/a

-US$47m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$9mUS$424k

-US$46m

Compensation vs Market: Insufficient data to establish whether Wei-Wu's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Wei-Wu's compensation has increased whilst the company is unprofitable.

CEO

Wei-Wu He (61 yo)

less than a year
Tenure

Dr. Wei-Wu He, PhD, is Co-Founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences-focused venture fund established in 2000. He serves as Executive Chairman of the Board at C...

Leadership Team

NamePositionTenureCompensationOwnership
Wei-Wu He
Executive Chairman of the Board & Principal Executive Officerless than a yearno data9.78%
$ 211.1k
Kun Qian
VP & Global Controller4.4yrsno datano data
Chunhua Wang
Chief Operating Officer8.3yrsno datano data
Wei Gao
General Counsel3.4yrsno datano data
Wei Zhang
Senior Vice President1.8yrsno data0.0098%
$ 211.5
Hai Huang
Chief Commercial Officer & GM2.4yrsno datano data
James E. Goldschmidt
Chief Business Officerno datano datano data
Junping Chen
Senior VP of Medical of US & Chief Medical Officer of Chinano datano datano data
2.9yrs
Average Tenure
55.5yo
Average Age

Experienced Management: CASI.F's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Wei-Wu He
Executive Chairman of the Board & Principal Executive Officer14.3yrsno data9.78%
$ 211.1k
Zuie-Chin Huang
Independent Directorless than a yearno data0%
$ 0
Barbara Krebs-Pohl
Independent Directorless than a yearno datano data
Sue Eckhardt
Member of Scientific Advisory Board19.9yrsno datano data
Y. Alexander Wu
Independent Director13.2yrsno data0.17%
$ 3.6k
Thomas Folinsbee
Independent Directorno datano datano data
Ghassan Abou-Alfa
Member of Clinical Advisory Board10.9yrsno datano data
Zhenbo Su
Independent Director3.3yrsno datano data
Robert Mayer
Member of Clinical Advisory Board10.9yrsno datano data
Xuebo Zeng
Independent Director10.4yrsno datano data
10.9yrs
Average Tenure
59yo
Average Age

Experienced Board: CASI.F's board of directors are seasoned and experienced ( 10.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 20:39
End of Day Share Price 2026/06/09 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CASI Pharmaceuticals, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathaniel CallowayEdison Investment Research
Sean LeeH.C. Wainwright & Co.
Mi ZhouMaxim Group